Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Summavac R is an oral bacterial ribosomal vaccine developed by Laboratorio Pablo Cassará for the prevention and treatment of recurrent respiratory tract infections. It consists of a combination of bacterial ribosomal antigens derived from *Klebsiella pneumoniae*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, and *Haemophilus influenzae*, along with membrane antigens from *Klebsiella pneumoniae*. The vaccine acts as an immunostimulant, triggering both innate and adaptive immune responses by mimicking a natural infection. It stimulates the production of secretory IgA and activates T-lymphocytes and natural killer cells, thereby enhancing the body's defense against common respiratory pathogens. It is typically administered as oral tablets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Summavac R.